Skip to content
Wugen logo — Engineering the Next Generation of Off-the-Shelf Cell Therap...

Wugen

Engineering the Next Generation of Off-the-Shelf Cell Therapies

Founded 2018 United States St. Louis, United States 51 employees Series C Total: $323.00M Biotechnology, Health and Wellness

General Information

Company Name Wugen
Founded Year 2018
Location United States St. Louis, United States
Employees 51
Industries Biotechnology, Health and Wellness
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Wugen. To contact Wugen, visit wugen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Wugen compare?

A PDF of Wugen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Wugen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Wugen

Wugen is a clinical-stage biotechnology company with the slogan "Engineering the Next Generation of Off-the-Shelf Cell Therapies." Founded in 2018, the company is based out of St. Louis, Missouri and San Diego, California. Wugen is focused on developing off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer, utilizing its proprietary Moneta platform and deep genomic engineering expertise. This innovative approach aims to pioneer a new class of memory NK cell therapies to address hematological and solid tumor malignancies. The company has recently secured a significant $172.00M Series B investment on 15 July 2021 from noteworthy investors including Abingworth, Aisling Capital, Alexandria Venture Investments, Alpha Wave Global, Fidelity, Intermediate Capital Group, Lightchain, Tybourne Capital Management, Velosity Capital, and LYZZ CAPITAL. Wugen's cutting-edge work and sizeable investment signify its potential to make a significant impact in the field of biotechnology and cancer therapeutics.

Business keywords: cell therapy, off-the-shelf, NK cells, CAR-T cells, cancer, Moneta platform, genomic engineering, immuno-oncology, AML, solid tumors, clinical-stage, St. Louis, San Diego, memory NK cells

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $115.00M 8
Abingworth, RiverVest +6
01 Aug 2025
Series B $172.00M 11
Abingworth, RiverVest +9
01 Jul 2021
Series A $36.00M -
01 Apr 2020
Seed Undisclosed -
01 Jan 2019
Spinout Undisclosed 1
Washington University in St. Louis
01 Jan 2018

Wugen Alternatives & Competitors

View All Alternatives
Wugen vs

‘Off-the-Shelf’ Curative Cell Therapies

Pre-Seed
3 employees
Biotechnology, Health and Wellness
Wugen vs

Pioneering thymus-empowered T-cell platform to fight cancer and infection

Grant
35 employees
Biotechnology, Health Care
Wugen vs
Turnstone Biologics
Turnstone Biologics United States

Developing next-generation TIL-based therapies to treat and cure solid tumors.

Series D
64 employees
Biotechnology, Health and Wellness

FAQ About Wugen

Engineering the Next Generation of Off-the-Shelf Cell Therapies
Wugen was founded in 2018.
Wugen is headquartered in St. Louis, United States.
Wugen operates in Biotechnology and Health and Wellness. Its work centres on cell therapy, off-the-shelf, NK cells and CAR-T cells.
Wugen has approximately 51 employees.
Wugen has completed 5 funding rounds, raising a total of $323.00M. The latest funding stage is Series C.
Top alternatives and competitors to Wugen include Cell BioEngines, Inc, Smart Immune, Turnstone Biologics, Acepodia, Tessa Therapeutics Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Wugen and Cell BioEngines, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Wugen, https://bouncewatch.com/company/wugen, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout